CYTHW
Income statement / Annual
Last year (2023), Cyclo Therapeutics, Inc.'s total revenue was $1.08 M,
a decrease of 21.76% from the previous year.
In 2023, Cyclo Therapeutics, Inc.'s net income was -$20.06 M.
See Cyclo Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.08 M
|
$1.38 M
|
$1.59 M
|
$903,376.00
|
$1.01 M
|
$1.01 M
|
$1.24 M
|
$1.50 M
|
$950,455.00
|
$1.57 M
|
| Cost of Revenue |
$98,458.00 |
$138,929.00 |
$156,080.00 |
$66,398.00 |
$75,493.00 |
$105,026.00 |
$132,918.00 |
$198,429.00 |
$124,425.00 |
$272,641.00 |
| Gross Profit |
$977,947.00 |
$1.24 M |
$1.43 M |
$836,978.00 |
$931,705.00 |
$906,451.00 |
$1.10 M |
$1.30 M |
$826,030.00 |
$1.29 M |
| Gross Profit Ratio |
0.91 |
0.9 |
0.9 |
0.93 |
0.93 |
0.9 |
0.89 |
0.87 |
0.87 |
0.83 |
| Research and Development
Expenses |
$14.18 M
|
$9.00 M
|
$9.15 M
|
$6.10 M
|
$4.87 M
|
$2.71 M
|
$2.29 M
|
$1.86 M
|
$658,505.00
|
$94,133.00
|
| General & Administrative
Expenses |
$5.66 M
|
$7.81 M
|
$6.50 M
|
$3.68 M
|
$3.43 M
|
$2.43 M
|
$2.62 M
|
$2.64 M
|
$2.22 M
|
$1.53 M
|
| Selling & Marketing
Expenses |
$3,902.00
|
$13,060.00
|
$18,336.00
|
$5,006.00
|
$5,885.00
|
$5,643.00
|
$7,847.00
|
$7,159.00
|
$7,569.00
|
$10,899.00
|
| Selling, General &
Administrative Expenses |
$6.83 M
|
$7.82 M
|
$6.52 M
|
$3.68 M
|
$3.44 M
|
$2.44 M
|
$2.63 M
|
$2.65 M
|
$2.23 M
|
$1.55 M
|
| Other Expenses |
$0.00 |
$30,500.00 |
$27,535.00 |
$19,951.00 |
$13,976.00 |
$13,945.00 |
$19,771.00 |
$130,953.00 |
$202,015.00 |
$217,518.00 |
| Operating Expenses |
$21.04 M |
$16.85 M |
$15.70 M |
$9.80 M |
$8.32 M |
$5.16 M |
$4.95 M |
$4.65 M |
$3.09 M |
$1.86 M |
| Cost And Expenses |
$21.13 M |
$16.99 M |
$15.85 M |
$9.86 M |
$8.40 M |
$5.27 M |
$5.08 M |
$4.85 M |
$3.22 M |
$2.13 M |
| Interest Income |
$0.00 |
$12,474.00 |
$3,405.00 |
$19,802.00 |
$12,027.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$28,603.00 |
$31,290.00 |
$33,673.00 |
| Depreciation &
Amortization |
$19,276.00
|
$19,481.00
|
$16,827.00
|
$12,763.00
|
$5,681.00
|
$10,124.00
|
$9,271.00
|
$107,096.00
|
$169,030.00
|
$152,446.00
|
| EBITDA |
-$20.03 M
|
-$15.60 M
|
-$14.27 M
|
-$8.95 M
|
-$7.39 M
|
-$4.24 M
|
-$3.82 M
|
-$4.09 M
|
-$2.23 M
|
-$406,568.00
|
| EBITDA Ratio |
-18.61 |
-11.45 |
-8.98 |
-9.92 |
-7.19 |
-4.2 |
-3.1 |
-2.15 |
-2.21 |
-0.26 |
| Operating Income Ratio
|
-18.63
|
-11.35
|
-9
|
-9.92
|
-7.34
|
-4.22
|
-3.11
|
-2.8
|
-2.53
|
-0.36
|
| Total Other
Income/Expenses Net |
-$7,245.00
|
$170,998.00
|
$3,405.00
|
$19,802.00
|
$12,027.00
|
$11,773.00
|
$10,261.00
|
-$17,954.00
|
-$24,620.00
|
-$30,373.00
|
| Income Before Tax |
-$20.06 M |
-$15.45 M |
-$14.29 M |
-$8.94 M |
-$7.53 M |
-$4.26 M |
-$3.83 M |
-$4.22 M |
-$2.43 M |
-$592,687.00 |
| Income Before Tax Ratio
|
-18.63
|
-11.23
|
-9.01
|
-9.9
|
-7.48
|
-4.21
|
-3.1
|
-2.81
|
-2.56
|
-0.38
|
| Income Tax Expense |
$0.00 |
-$170,998.00 |
$18,522.00 |
-$18,530.00 |
$141,745.00 |
$11,773.00 |
$0.00 |
$28,603.00 |
$120,000.00 |
$33,673.00 |
| Net Income |
-$20.06 M |
-$15.28 M |
-$14.31 M |
-$8.92 M |
-$7.67 M |
-$4.26 M |
-$3.83 M |
-$4.22 M |
-$2.55 M |
-$592,687.00 |
| Net Income Ratio |
-18.63 |
-11.11 |
-9.02 |
-9.88 |
-7.62 |
-4.21 |
-3.1 |
-2.81 |
-2.68 |
-0.38 |
| EPS |
-1.23 |
-1.81 |
-2.25 |
-5.58 |
-7.09 |
-5.2 |
-5.32 |
-6.67 |
-4.54 |
-1.17 |
| EPS Diluted |
-1.23 |
-1.81 |
-2.25 |
-5.58 |
-7.09 |
-5.2 |
-5.32 |
-6.67 |
-4.54 |
-1.17 |
| Weighted Average Shares
Out |
$16.33 M
|
$8.44 M
|
$6.37 M
|
$1.60 M
|
$1.08 M
|
$817,568.00
|
$720,371.00
|
$633,544.00
|
$562,094.00
|
$505,431.00
|
| Weighted Average Shares
Out Diluted |
$16.33 M
|
$8.44 M
|
$6.37 M
|
$1.60 M
|
$1.08 M
|
$817,568.00
|
$720,371.00
|
$633,544.00
|
$562,094.00
|
$505,431.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
